Madrigal Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 73 to 87.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks matches up against that of all other stocks.
Over 100 years of market history reveals that the top-performing stocks typically have an RS Rating of at least 80 as they launch their biggest runs.
Madrigal Pharmaceuticals is building a consolidation with a 377.46 entry. See if it can break out in volume at least 40% higher than normal.
Madrigal Pharmaceuticals showed 0% EPS growth in the latest quarterly report. Sales rose 0%. The next quarterly results are expected on or around Aug. 6.
The company earns the No. 54 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
